TCM
IBRX icon

Traynor Capital Management’s ImmunityBio IBRX Stock Holding History

Traynor Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.5K Buy
+2,000
New +$15.1K ﹤0.01% 363
2025
Q1 		– Sell
-6,500
Closed -$16.6K – 282
2024
Q4 		$16.6K Sell
6,500
-9,900
-60% -$41.2K ﹤0.01% 282
2024
Q3 		$61K Buy
16,400
+6,800
+71% +$31.5K ﹤0.01% 256
2024
Q2 		$60.7K Buy
9,600
+5,600
+140% +$36.9K ﹤0.01% 251
2024
Q1 		$21.5K Buy
4,000
+1,000
+33% +$4.53K ﹤0.01% 266
2023
Q4 		$15.1K Buy
+3,000
New +$9.41K ﹤0.01% 237

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Traynor Capital Management's IBRX Position: Q2 2026 in Review

Traynor Capital Management opened a new position in ImmunityBio (IBRX) in Q2 2026: 19,200 shares worth $168K. The stake represents 0.01% of the portfolio and ranks #331 among its holdings. This is a return to the name: Traynor Capital Management previously reported a position in IBRX as recently as Q2 2025.

Traynor Capital Management first reported a position in IBRX in Q3 2023 and has held it in 9 quarters since. The position peaked at $194K in Q2 2024. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Traynor Capital Management held 19,200 shares of ImmunityBio worth $168K as of Q2 2026.
  • ImmunityBio was a new Traynor Capital Management position in Q2 2026.
  • ImmunityBio made up 0.01% of Traynor Capital Management's portfolio in Q2 2026, its #331 holding.
  • Traynor Capital Management first reported a position in ImmunityBio in Q3 2023 and has held it in 9 quarters since.
  • Traynor Capital Management's ImmunityBio position peaked at $194K in Q2 2024.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Traynor Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.